Breckenridge’s 40 mg Cymbalta generic approved
The Food and Drug Administration has approved a new dosage strength of Breckenridge Pharmaceutical’s Cymbalta generic (duloxetine tablets). The Boca Raton, Fla.-based company received approval for its 40-mg dosage strength tablets.
The Cymbalta generic is indicated to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy and chronic musculoskeletal disorder. The product will be manufactured and supplied by Breckenridge’s vertically integrated parent company Esteve Pharmaceuticals, Breckenridge said.
The company noted that the drug’s approximate market size is roughly $25 million annually.
The Cymbalta generic is indicated to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy and chronic musculoskeletal disorder. The product will be manufactured and supplied by Breckenridge’s vertically integrated parent company Esteve Pharmaceuticals, Breckenridge said.
The company noted that the drug’s approximate market size is roughly $25 million annually.